Acurx Pharmaceuticals, Inc.
ACXP
$3.10
$0.3211.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.34M | 1.60M | 1.75M | 1.55M | 1.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.62M | 2.03M | 2.27M | 2.15M | 2.79M |
| Operating Income | -1.62M | -2.03M | -2.27M | -2.15M | -2.79M |
| Income Before Tax | -1.58M | -1.99M | -2.25M | -2.15M | -2.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.58M | -1.99M | -2.25M | -2.15M | -2.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.58M | -1.99M | -2.25M | -2.15M | -2.78M |
| EBIT | -1.62M | -2.03M | -2.27M | -2.15M | -2.79M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.73 | -1.23 | -1.89 | -2.15 | -3.29 |
| Normalized Basic EPS | -0.45 | -0.77 | -1.18 | -1.34 | -2.05 |
| EPS Diluted | -0.73 | -1.23 | -1.89 | -2.15 | -3.29 |
| Normalized Diluted EPS | -0.45 | -0.77 | -1.18 | -1.34 | -2.05 |
| Average Basic Shares Outstanding | 2.17M | 1.63M | 1.19M | 1.00M | 846.50K |
| Average Diluted Shares Outstanding | 2.17M | 1.63M | 1.19M | 1.00M | 846.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |